340450.KQ GC Genome Corporation

Healthcare Biotechnology KOSDAQ
9,100 KRW
Close of Oct 30, 2026
4,100 10,480
Market cap
KRW 215B
P/E
37.5x
P/B
2.69x
ROE
4.0%
Dividend yield
-
Fundamental score
1.1/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 340450.KQ undervalued?

Graham number
Price9,100
Graham value4,295
Premium111.9%

340450.KQ trades 111.9% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GC Genome Corporation fundamental analysis

6 of 22 checks passed

ROE 0/2

Low return on equity (4.0%), below 10%.

ROA 1/1

Return on assets (3.6%) is above the industry median (-10.1%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (421.8%) is above the industry median (4.8%).

Revenue Growth 1/2

Revenue grew 9.4% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 1/1

EBIT is 21.7x against interest expense, well covered.

PE vs Market 0/1

PE (37.5x) is above the market median (11.3x).

PE vs Industry 0/1

PE (37.5x) is above the industry median (28.9x).

PBV 0/1

Price to book (2.7x) is above the industry median (2.4x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 101.0, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

GC Genome Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GC Genome Corporation

GC Genome Corporation operates as a clinical genome analysis company in South Korea. It offers hereditary cancer, tissue and liquid biopsy genetic, blood cancer, and homologous recombination deficiency tests under the Green Plan names; Guardant360, a blood genetic profiling test; Guardant Reveal, a liquid biopsy microscopic residual disease detection and recurrence monitoring test; and genetic rare disease testing services for chromosomal microarray, targeted exome sequencin…

Full company profile